Abstract

Tyrosine kinase inhibitors [ TKI’s] in chronic myeloid leukemia has made once incurable disease without stem cell transplant to become like chronic disease like diabetes and hypertension. These agents having some of distressing adverse events due to long term duration of treatment. The cutaneous adverse events make the patient non sociable, depressing and having impact on quality of life. The second generation BCR-ABL TKI nilotinib implicated in multiple dermatological issues [1]. Here we are reporting a case of Nilotinib Induced thinning and loss of eyebrow hair in a chronic phase chronic myeloid leukemia patient.